Description

LETRIOVAC 2.5 MG

Indications

LETRIOVAC 2.5 MG is primarily indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is specifically used in cases where the cancer is advanced or has metastasized. The medication is effective in reducing the risk of recurrence in patients who have undergone surgery or radiation therapy. In addition, LETRIOVAC may be utilized in combination with other therapies to enhance treatment outcomes.

Mechanism of Action

LETRIOVAC contains the active ingredient letrozole, which is classified as an aromatase inhibitor. Its primary mechanism of action involves the inhibition of aromatase, an enzyme responsible for converting androgens into estrogens in peripheral tissues. By decreasing estrogen levels in the body, LETRIOVAC effectively reduces the stimulation of estrogen-dependent tumors, leading to a decrease in tumor growth and proliferation. This mechanism is particularly beneficial in hormone receptor-positive breast cancers, where estrogen plays a critical role in tumor development.

Pharmacological Properties

LETRIOVAC is rapidly absorbed following oral administration, with peak plasma concentrations typically reached within 1 to 2 hours. The drug has a high bioavailability of approximately 99.9% and is extensively metabolized in the liver, primarily via cytochrome P450 enzymes. The elimination half-life of letrozole is approximately 2 days, allowing for once-daily dosing. LETRIOVAC is excreted mainly through urine, with less than 10% of the dose appearing unchanged. Its pharmacokinetic profile supports its use in long-term management of breast cancer.

Contraindications

LETRIOVAC is contraindicated in patients with a known hypersensitivity to letrozole or any of its components. It should not be used in premenopausal women, as it is not effective in this population due to the presence of ovarian estrogen production. Additionally, patients with severe liver impairment should avoid LETRIOVAC, as liver function can significantly affect the metabolism and clearance of the drug. Pregnant or breastfeeding women should also refrain from using this medication due to potential risks to the fetus or infant.

Side Effects

Common side effects associated with LETRIOVAC include hot flashes, joint pain, fatigue, and nausea. Other less frequent but more serious side effects may include osteoporosis, cardiovascular events, and liver function abnormalities. Patients should be monitored regularly for signs of these adverse effects, especially in long-term therapy. It is essential to report any unusual symptoms to a healthcare provider promptly to manage potential complications effectively.

Dosage and Administration

The recommended dosage of LETRIOVAC is 2.5 mg taken orally once daily, with or without food. It is crucial for patients to adhere to the prescribed dosage and schedule to ensure optimal therapeutic outcomes. In cases where a dose is missed, patients should take it as soon as they remember, unless it is almost time for the next dose. In such instances, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose to make up for a missed one is not advised.

Interactions

LETRIOVAC may interact with various medications, potentially altering its effectiveness or increasing the risk of adverse effects. Notably, strong inhibitors of cytochrome P450 2A6 and 2C19 may increase plasma concentrations of letrozole. Conversely, medications that induce these enzymes may decrease its effectiveness. Patients should inform their healthcare providers of all medications, supplements, and herbal products they are taking to assess potential interactions. Special caution should be exercised when considering concurrent use with anticoagulants, as the risk of bleeding may be heightened.

Precautions

Before initiating treatment with LETRIOVAC, healthcare providers should conduct a thorough assessment of the patient’s medical history, particularly regarding bone health and cardiovascular status. Patients with a history of osteoporosis or fractures should be monitored closely, as letrozole can contribute to bone density loss. Regular bone density assessments may be warranted. Additionally, patients with a history of cardiovascular disease should be evaluated for potential risks associated with the use of LETRIOVAC. It is essential to maintain open communication with healthcare providers throughout the treatment process.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of LETRIOVAC in the treatment of hormone receptor-positive breast cancer. In a pivotal Phase III trial, letrozole was shown to significantly improve disease-free survival compared to placebo in postmenopausal women with early-stage breast cancer. Furthermore, studies have indicated that LETRIOVAC is effective in reducing the risk of recurrence in patients with advanced disease. Long-term follow-up data have also suggested that letrozole may improve overall survival rates in this patient population, establishing it as a cornerstone of therapy in hormone receptor-positive breast cancer management.

Conclusion

LETRIOVAC 2.5 MG is a vital therapeutic option for postmenopausal women with hormone receptor-positive breast cancer. Its mechanism of action as an aromatase inhibitor effectively reduces estrogen levels, thereby inhibiting tumor growth. While generally well-tolerated, it is essential for patients to be aware of potential side effects and drug interactions. Regular monitoring and communication with healthcare providers can help manage these risks effectively. Overall, LETRIOVAC represents a significant advancement in the treatment of breast cancer, contributing to improved patient outcomes.